Direct answer: which obesity-related conditions does bariatric surgery actually improve?

Bariatric surgery has documented effects on at least 10 major obesity-related conditions, and the effect sizes are among the largest in medicine. The 2023 Cui meta-analysis of 40 BMI-matched cohort studies showed 62% reduction in cardiovascular mortality. The SPLENDID JAMA 2022 study of 30,318 patients showed 32% reduction in cancer incidence and 48% in cancer mortality. The MOSAIC 2024 JACC study showed 42% reduction in major cardiovascular events in obese patients with sleep apnea. The Alqahtani 2026 meta-analysis showed 79% reduction in osteoarthritis diagnosis. The BRAVES Lancet 2023 trial showed 84% improvement in liver fibrosis. The Almutairi 2024 meta-analysis showed 45% reduction in infertility.

These are not isolated findings. They are connected, because obesity is a hub disease that drives many spokes through shared mechanisms.

My short rule is this:

• Multiple comorbidities (3+ active conditions): bariatric surgery addresses the hub, not just each spoke. This is the strongest population for surgery.
• Single severe comorbidity (severe HTN refractory to 4+ meds, severe OSA AHI 50+, severe MASH with fibrosis): surgery is often more effective than maximum medical therapy for that single condition.
• Wanting cardiovascular or cancer primary prevention with BMI above 35: surgery has stronger and longer evidence than any pharmacologic alternative.
• Mental health considerations: surgery improves depression for most but documented risks for self-harm and alcohol use disorder require pre-operative screening and procedure selection.

The master decision guide: all 10 conditions in one table

Condition	Effect Size	Best procedure	Read more
PMOS / PCOS	Up to 61% restoration of ovulatory cycles; metformin equivalence broken	Sleeve or bypass	PMOS article
OSA / Sleep apnea	42% MACE reduction; AHI reduction 70%+	Sleeve preferred	OSA article
MASLD / MASH	84% fibrosis improvement at 1 year (BRAVES)	Bypass slightly stronger metabolically	MASLD article
Hypertension	50%+ resolution at 5 years (GATEWAY)	Either	Hypertension article
GERD	Bypass resolves; sleeve can worsen	Bypass for severe GERD; sleeve otherwise	GERD article
Infertility (female)	45% reduction; IVF live birth doubles	Either	Fertility article
Osteoarthritis	79% reduction in OA diagnosis	Sleeve (less bone loss)	Osteoarthritis article
Cardiovascular disease	62% CV mortality reduction; 73% heart failure reduction	Either	Cardiovascular article
Cancer	32% incidence, 48% mortality (SPLENDID)	Sleeve (CRC signal concern with bypass)	Cancer article
Depression / Mental health	Substantial symptom improvement; real risks documented	Sleeve for AUD risk; bypass acceptable otherwise	Mental health article

The 30-second summary

Obesity is rarely a single disease. Most bariatric candidates carry 3 to 6 obesity-related conditions simultaneously: type 2 diabetes, hypertension, dyslipidemia, sleep apnea, fatty liver disease, joint pain, reproductive disruption, depression, and elevated cancer risk. These conditions share biological mechanisms (insulin resistance, chronic inflammation, hormonal dysregulation, sleep disruption, mechanical loading, microbiome alteration). This is the “metabolic hub” model: obesity is the upstream driver, and individual diseases are downstream spokes. Bariatric surgery works because it corrects the hub. The cumulative effect on the published literature is striking: cardiovascular mortality drops 62% (Cui 2023, 40-study meta-analysis), cancer mortality drops 48% (SPLENDID JAMA 2022), heart failure incidence drops 73% in T2D patients (Höskuldsdóttir 2021), osteoarthritis incidence drops 79% (Alqahtani 2026), liver fibrosis improves in 84% (BRAVES 2023), and depression symptoms decrease at all follow-up points. The SOS study followed patients up to 20 years and showed sustained 30% all-cause mortality reduction throughout. The comparison with GLP-1 medications is favorable but not absolute: head-to-head meta-analyses show surgery produces 35-55% better outcomes across most endpoints, but GLP-1s now have RCT-level evidence for several conditions where surgery still relies on observational data. The honest picture also includes real risks: bone mineral density loss, alcohol use disorder signal (especially with bypass), modest suicide and self-harm signal, and procedure-specific complications. The choice between sleeve and bypass matters more than is commonly discussed, and depends on the specific comorbidity profile of each patient. Here is the consolidated picture, condition by condition.

Why obesity drives so many parallel diseases: the metabolic hub

Before going condition by condition, it helps to understand why bariatric surgery works on so many seemingly unrelated diseases.

Obesity is not a single disease state. It is a network of biological dysfunctions that share upstream drivers. Five mechanisms matter most across nearly every comorbidity in this guide.

Insulin resistance and hyperinsulinemia. Chronically elevated insulin drives T2D, hypertension (via renal sodium retention and sympathetic activation), dyslipidemia, MASLD, PCOS/PMOS through ovarian androgen excess, and accelerated atherogenesis. Reverse insulin resistance and you affect all of these in parallel.

Chronic systemic inflammation. Visceral adipose tissue secretes TNF-α, IL-6, leptin, and CRP. These drive cardiovascular disease, cancer, joint inflammation, depression (cytokine-neurotransmitter interactions), and impaired wound healing. Reduce inflammation and the same conditions respond.

Hormonal dysregulation. Adipose tissue produces estrogens (via aromatase), affects thyroid function, alters cortisol metabolism, suppresses testosterone in men, drives anovulation in women. The hormonal milieu connects fertility, cancer, mental health, and cardiometabolic outcomes.

Mechanical and respiratory loading. Body mass directly loads joints (each pound = 4 pounds knee force) and compresses the upper airway during sleep. Both OSA and osteoarthritis respond to this mechanical dimension.

Microbiome and metabolite changes. Gut microbiome alterations, bile acid disturbances, and short-chain fatty acid changes connect obesity to colorectal cancer, MASLD, immune function, and possibly mood through gut-brain signaling.

When you understand the mechanisms, the breadth of bariatric surgery effects stops looking like coincidence. Lose 25-30% of body weight, sustain it for years, and each of these mechanisms partially reverses. The downstream diseases respond accordingly.

This is also why patients with multiple comorbidities benefit most from surgery: each individual disease has multiple medications that address only some of the upstream drivers. Surgery addresses the upstream drivers themselves.

Reproductive and hormonal: PMOS, fertility, and the female metabolic profile

The reproductive endocrine effects of bariatric surgery are some of the most dramatic in medicine, particularly for women.

PMOS (formerly PCOS, renamed by The Lancet in May 2026). Polycystic ovary syndrome remains one of the most common endocrine disorders in women, and obesity drives its severity. Bariatric surgery resolves PMOS in a majority of patients within 12 months. Ovulatory cycles return, hyperandrogenism resolves, insulin resistance corrects, and metabolic markers normalize. The pooled comparison with metformin alone shows surgery is approximately twice as effective for restoring fertility in obese women with PMOS (34.9% pregnancy rate vs 17.1%).

Fertility. The 2024 Almutairi meta-analysis in the Journal of Clinical Medicine pooled studies of women with obesity-related infertility and showed bariatric surgery reduced infertility by 45% (RR 0.55, p<0.00001), miscarriage by 49% (RR 0.51), and irregular menstrual cycles substantially. The Grzegorczyk-Martin 2020 cohort showed IVF live birth per transfer doubled from 9.3% in non-operated obese controls to 20% post-bariatric.

For men, the picture is more nuanced: testosterone and sexual function improve, but sperm parameters do not consistently improve in the 2025 Human Reproduction Update meta-analysis.

For full timing guidance (12-18 months wait before conception, GLP-1 washout protocols, contraception during the weight loss phase), and the male fertility caveats, see the full fertility article.

Cardiometabolic: hypertension, MASLD, and cardiovascular disease

These three conditions share the most overlapping mechanisms (insulin resistance, inflammation, endothelial dysfunction) and respond most consistently to bariatric surgery as a single intervention.

Hypertension. The GATEWAY 5-year follow-up published in JACC showed sustained hypertension resolution in approximately 50% of bariatric patients, with most others on substantially fewer antihypertensive medications. Blood pressure typically drops within 4-8 weeks post-op. See the hypertension article for procedure-specific data, medication management timeline, and the GLP-1 comparison.

MASLD / MASH (formerly NAFLD / NASH). The BRAVES Lancet 2023 trial demonstrated 84% fibrosis improvement at 1 year post-bariatric, vastly exceeding any current pharmacologic intervention including the recently approved resmetirom. For patients with metabolic dysfunction-associated steatotic liver disease progressing toward cirrhosis, bariatric surgery may be the most effective single intervention available. See the MASLD article for procedure differences and HCC prevention implications.

Cardiovascular disease. The 2023 Cui meta-analysis of 40 BMI-matched cohort studies showed bariatric surgery reduces cardiovascular mortality by 62% (HR 0.38), MACE by 35-45%, and cancer mortality by 54%. The 2021 Höskuldsdóttir Swedish cohort showed heart failure incidence dropped 73% (HR 0.27) and atrial fibrillation 41% (HR 0.59) in patients with T2D and obesity. For comparison, the SELECT trial showed semaglutide reduces MACE by 20%. The 2025 head-to-head meta-analysis showed surgery produces 43% lower mortality and 35% lower MACE than GLP-1 therapy. See the cardiovascular article for the full breakdown including LV function changes and patient selection.

Sleep and breathing: OSA

Obstructive sleep apnea is present in roughly 70% of bariatric candidates, often undiagnosed pre-operatively. The MOSAIC 2024 study published in JACC followed obese OSA patients and showed bariatric surgery reduced major adverse cardiovascular events by 42% and all-cause mortality by 37% over 10 years compared to usual care. AHI typically drops 60-80% within 6 months post-bariatric.

The SURMOUNT-OSA trial published in NEJM 2024 showed tirzepatide produces meaningful AHI reduction, providing the first RCT-level GLP-1 data for OSA. Surgery still produces larger and more durable AHI reductions. See the OSA article for procedure-specific outcomes and CPAP weaning protocols.

Digestive: GERD and the procedure question

GERD is the area where the choice between sleeve and bypass matters most directly. The sleeve gastrectomy can worsen pre-existing GERD in a subset of patients, while Roux-en-Y bypass is the most effective surgical anti-reflux operation available.

The SLEEVEPASS 10-year RCT (PMID 35731535) and SM-BOSS 10-year data show GERD outcomes diverge substantially by procedure. Post-sleeve Barrett’s esophagus incidence reaches 11.6% in the Qumseya 2021 meta-analysis, an important long-term consideration.

For patients with significant pre-existing GERD, Barrett’s history, hiatal hernia, or strong family history of esophageal adenocarcinoma, bypass is the indicated procedure. For patients without these risk factors, sleeve has the broader profile of advantages with manageable GERD considerations. See the GERD article for full procedure selection guidance.

Cancer: the SPLENDID data and the colorectal nuance

The 2022 SPLENDID study published in JAMA followed 30,318 patients at Cleveland Clinic at median 6.1 years and found bariatric surgery reduces obesity-associated cancer incidence by 32% and cancer mortality by 48%. The effect is dose-dependent: more weight loss equals more cancer reduction.

By cancer type (2023 meta-analysis):

• Endometrial: 62% reduction (largest, given strongest obesity association)
• Liver/HCC: 65% reduction
• Ovarian: 55% reduction
• Pancreatic: 48% reduction
• Postmenopausal breast: 45% reduction
• Gallbladder: 59% reduction
• Colorectal: 37% reduction overall

The colorectal cancer story is more nuanced. Some long-term cohort studies (Mackenzie 2018 BJS, Nordic 5-country cohort) suggest possible increased CRC risk after Roux-en-Y gastric bypass at 10+ year follow-up, related to microbiome alterations and increased colonic bile acid exposure. The sleeve gastrectomy does not share this signal in published data and shows the strongest CRC protective effect when analyzed separately. For patients with elevated baseline colorectal cancer risk (Lynch syndrome, strong family history, IBD), this is a procedure-specific reason to prefer sleeve over bypass. See the cancer article for the full picture cancer by cancer.

Musculoskeletal: osteoarthritis

The 2026 Alqahtani meta-analysis in World Journal of Surgery pooled 12 studies and 12,000 patients and found bariatric surgery reduces osteoarthritis diagnosis by 79% (OR 0.21). WOMAC pain and function scores improve substantially within the first year and persist to 5-7 years (King 2022).

The data on bariatric surgery before joint replacement is more mixed than commonly told. The 2025 meta-analysis of 6.2 million patients found different results by joint: hip arthroplasty outcomes improve substantially after bariatric (lower PJI, lower mechanical loosening), while knee arthroplasty shows higher revision rates post-bariatric (RR 1.28).

The STEP 9 trial in NEJM 2024 showed semaglutide reduces WOMAC pain by 41.7 vs 27.5 placebo, providing the first RCT-level GLP-1 data for OA. Effect sizes are comparable in the first year; surgery produces larger weight loss and longer durability. See the osteoarthritis article for the bone health trade-offs that matter for this population.

Mental health: depression improves for most, real risks documented

This is the most nuanced topic in the bariatric literature.

The 2025 Obesity Reviews meta-analysis of 13,146 patients showed depressive symptoms improved substantially at all follow-up points after bariatric surgery (effect size g = -0.91 at 5-12 months). The 2023 umbrella review reported OR 0.49 for depression improvement.

But the 2018 Neovius study in Lancet Diabetes Endocrinology, pooling two Swedish cohorts of 40,000+ patients, found bariatric surgery was associated with increased risk of suicide and non-fatal self-harm vs matched non-surgical controls. The 2018 Azam meta-analysis found alcohol use disorder roughly doubled (pooled OR 1.83) at 3+ years post-bypass.

These risks are concentrated in patients with prior mental health history (93% of post-bariatric self-harm events occurred in patients with pre-existing mental disorders). The absolute risks are low and do not justify avoiding surgery in appropriate candidates, but they justify pre-operative psychological evaluation, careful procedure selection (sleeve preferred for AUD risk profile), and structured post-operative mental health follow-up. See the mental health article for the full picture including procedure differences and the adolescent caveat.

How bariatric surgery compares to GLP-1 medications across all conditions

This is the cross-cutting question patients now ask in nearly every consultation. The honest answer requires looking at the data by condition.

Where GLP-1s now have RCT-level evidence:

• Cardiovascular disease (SELECT NEJM 2023): semaglutide reduces MACE by 20% in non-diabetic patients with established CVD.
• Knee osteoarthritis (STEP 9 NEJM 2024): semaglutide reduces WOMAC pain by 14.1 points more than placebo.
• Heart failure with preserved EF (STEP-HFpEF): semaglutide improves symptoms and physical function.
• Sleep apnea (SURMOUNT-OSA NEJM 2024): tirzepatide reduces AHI substantially.

Where surgery still has stronger evidence:

• Long-term mortality: SOS up to 20 years; GLP-1 trials at maximum 4 years.
• Diabetes remission (T2D): surgery achieves complete remission in 30-50%; GLP-1s control but rarely cure.
• MASH/MASLD fibrosis: BRAVES 84% improvement; GLP-1 fibrosis data is much smaller magnitude.
• Cancer prevention: SPLENDID 32% incidence reduction; GLP-1 cancer data is emerging.
• PCOS/PMOS resolution: surgery resolves; GLP-1 helps but does not address ovarian function the same way.

The 2025 head-to-head meta-analysis comparing bariatric directly to GLP-1 therapy found surgery produced 43% lower all-cause mortality, 35% lower MACE, and 55% lower heart failure incidence.

The honest summary: surgery is more effective on most endpoints. GLP-1s are more effective than no intervention and produce real benefits with fewer barriers to entry. The right choice depends on the patient’s specific comorbidities, BMI, durability needs, financial considerations, and tolerance for surgery vs ongoing medication.

For many patients with severe obesity and multiple comorbidities, the sequence is: GLP-1 if surgery is delayed for any reason, then surgery when conditions allow, then continued metabolic management as needed.

When the data supports “surgery first” sequencing

For patients carrying multiple comorbidities, the decision is rarely about whether to intervene. It is about which intervention first.

The data supports surgery as the primary intervention in these scenarios:

• BMI above 40 with any obesity-associated condition.
• BMI 35-40 with two or more obesity-associated conditions (T2D, HTN, OSA, MASLD, etc).
• BMI above 35 with severe single comorbidity refractory to medical therapy (HTN on 4+ meds, OSA AHI >50, severe MASH with fibrosis).
• Patients failing GLP-1 therapy after 6-12 months of adequate trial.
• Patients seeking durable cardiovascular or cancer primary prevention with BMI above 35.
• Patients planning pregnancy where pre-pregnancy obesity drives reproductive risk.
• Patients with end-stage organ disease where weight reduction is required for transplant candidacy.

These align broadly with the 2022 ASMBS/IFSO indications for metabolic and bariatric surgery, which expanded surgical eligibility relative to the older 1991 NIH criteria.

What we still don’t know with certainty (the consolidated picture)

Across the 10 conditions covered in this guide, several gaps in the evidence base persist.

• No randomized controlled trial of bariatric surgery has been completed for primary cardiovascular endpoints, cancer endpoints, or all-cause mortality. The SOS study used non-randomized assignment. Effect sizes are large and consistent across observational cohorts, but RCT-level certainty does not exist.
• The relative effectiveness of sleeve vs bypass varies by comorbidity and is not fully settled for several outcomes. Most studies pool procedures together.
• Long-term GLP-1 outcomes beyond 5 years are unknown for cardiovascular endpoints, cancer endpoints, and overall mortality.
• The mechanisms of certain adverse signals post-bariatric (suicide, self-harm, alcohol use disorder, colorectal cancer) are not fully characterized, limiting precise patient selection.
• The interaction between bariatric surgery and concurrent or sequential GLP-1 therapy is largely uncharacterized, despite the rapidly growing population using both.
• Adolescent long-term outcomes are concerning for mental health (Bruze Lancet 2024 found no improvement at 10 years despite weight loss) and warrant more conservative thresholds in this age group.
• The optimal duration and intensity of post-operative monitoring for each comorbidity is not standardized.

I share these limitations with patients because they deserve to know what the evidence shows and where it remains incomplete.

What to do next

If you carry obesity and one or more of the conditions covered in this guide, the first step is a virtual consultation. We will review your specific comorbidity profile, current medications, family history, prior weight loss attempts, and overall metabolic picture. We will talk about whether surgery makes sense for you now, which procedure best matches your specific risk-benefit profile, and what pre-operative optimization and post-operative support look like.

You can request a free virtual evaluation, and my coordinator Lucia will reach out to schedule. We move at your pace, especially when multiple conditions are involved.

For specific conditions, the dedicated articles linked throughout this guide provide the full picture for that comorbidity, including procedure-specific data, GLP-1 comparisons, and patient selection nuances.

Bariatric surgery is not a single decision about weight loss. It is a decision about whether to address the metabolic hub that drives many parallel diseases. For patients carrying multiple obesity-related conditions, the published evidence supports it as one of the most effective interventions in medicine. You deserve the full picture before you decide.

Consolidated sources

This pillar guide draws on the primary evidence from each comorbidity-specific article. The most cited landmark studies across the guide:

1. Aminian A, Wilson R, Al-Kurd A, et al. Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity (SPLENDID study). JAMA. 2022;327(24):2423-2433. PMID: 35657620
2. Cui B, Wang G, Li P, et al. Disease-specific mortality and major adverse cardiovascular events after bariatric surgery: a meta-analysis of age, sex, and BMI-matched cohort studies. Int J Surg. 2023;109(3):389-400. PMID: 36928139
3. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial. J Intern Med. 2013;273(3):219-234.
4. Aminian A, Wang L, Al Jabri A, et al. Adverse Cardiovascular Outcomes in Patients With Obstructive Sleep Apnea and Obesity: Metabolic Surgery vs Usual Care (MOSAIC). J Am Coll Cardiol. 2024;84(7):589-602.
5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
6. Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (STEP 9). N Engl J Med. 2024.
7. Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of Bariatric Surgery in Obese Patients with Hypertension: The GATEWAY Randomized Trial. Circulation. 2018. 5-year follow-up: J Am Coll Cardiol. 2024.
8. Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401(10390):1786-1797.
9. Almutairi H, Aldhalea MS, Almaaz MA, et al. The Effectiveness of Bariatric Surgery on Treating Infertility in Women: A Systematic Review and Meta-Analysis. J Clin Med. 2024;13(18):5569. PMID: 39337056
10. Alqahtani A, et al. Effect of Bariatric Surgery on Osteoarthritis-Related Pain and Function: A Systematic Review and Meta-Analysis. World J Surg. 2026.
11. Höskuldsdóttir G, Ekelund J, Miftaraj M, et al. Potential Effects of Bariatric Surgery on the Incidence of Heart Failure and Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Obesity. J Am Heart Assoc. 2021;10(7):e019323. PMID: 33754795
12. Neovius M, Bruze G, Jacobson P, et al. Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies. Lancet Diabetes Endocrinol. 2018;6(3):197-207. PMID: 29329975
13. Budin C, et al. Depressive symptoms at short-, medium-, and long-term follow-up after bariatric surgical procedures: A systematic review and meta-analysis. Obesity Reviews. 2025.
14. Azam H, Shahrestani S, Phan K. Alcohol use disorders before and after bariatric surgery: a systematic review and meta-analysis. Ann Transl Med. 2018;6(8):148.
15. Teede HJ, et al. Renaming polycystic ovary syndrome to polycystic metabolic ovary syndrome (PMOS): rationale and implementation. The Lancet. May 2026.
16. Eisenberg D, Shikora SA, Aarts E, et al. 2022 ASMBS and IFSO: indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345-1356.

For the full citation list specific to each condition, see the dedicated articles linked throughout this guide.

---

Authored by Dr. Gabriela Rodríguez Ruiz, MD, PhD, FACS. This is the consolidated evidence guide drawing on the 10 condition-specific articles. Each spoke article provides the full clinical detail, procedure-specific guidance, and dedicated sources for that comorbidity. This pillar exists because obesity rarely arrives alone, and patients deserve to see how the evidence connects.